Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study

A primary analysis of the ASPIRE study found that the addition of carfilzomib to lenalidomide and dexamethasone (carfilzomib group) significantly improved progression‐free survival (PFS) compared with lenalidomide and dexamethasone alone (control group) in patients with relapsed multiple myeloma (RM...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Br J Haematol
Hlavní autoři: Dimopoulos, Meletios A., Stewart, A. Keith, Masszi, Tamás, Špička, Ivan, Oriol, Albert, Hájek, Roman, Rosiñol, Laura, Siegel, David, Mihaylov, Georgi G., Goranova‐Marinova, Vesselina, Rajnics, Péter, Suvorov, Aleksandr, Niesvizky, Ruben, Jakubowiak, Andrzej, San‐Miguel, Jesus, Ludwig, Heinz, Palumbo, Antonio, Obreja, Mihaela, Aggarwal, Sanjay, Moreau, Philippe
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2017
Témata:
Haematological Malignancy
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5412871/
https://ncbi.nlm.nih.gov/pubmed/28211560
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bjh.14549
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky